GLP-1 Market
LLY $1364.73 ▼ -3.8% NVO $40.30 ▼ -4.5% PFE $29.88 ▼ -3.0% VKTX $25.79 ▼ -7.8% KLRA $12.17 ▼ -4.9% GPCR $19.08 ▼ -6.3% RHHBY $59.45 ▼ -2.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

AADvac1

Company
Adam Boxer
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 6, 2026

Find a Clinical Trial Near Me

See recruiting studies for AADvac1 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06957418

    Alzheimer's Tau Platform: Master Protocol

    Not yet reported Paul S. Aisen 900 participants Est. completion 2028-08-31 7 sites Stand-alone
    Other conditions: Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
    View official trial listing →
  • Recruiting NCT NCT07173803

    The Progressive Supranuclear Palsy Clinical Trial Platform

    Not yet reported Adam Boxer 440 participants Est. completion 2030-09-28 21 sites Stand-alone
    Other conditions: Progressive Supranuclear Palsy(PSP)
    View official trial listing →
  • Completed NCT NCT01850238

    Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease

    Not yet reported Axon Neuroscience SE 30 participants Est. completion 2015-03 3 sites Stand-alone
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Completed NCT NCT02031198

    18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease

    Not yet reported Axon Neuroscience SE 25 participants Est. completion 2016-12 4 sites Stand-alone
    Other conditions: Alzheimer's Disease
    View official trial listing →
  • Completed NCT NCT02579252

    24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease

    Not yet reported Axon Neuroscience SE 208 participants Est. completion 2019-06 42 sites Stand-alone
    Other conditions: Alzheimer's Disease
    View official trial listing →
  • Status unknown NCT NCT03174886

    A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia

    Not yet reported Axon Neuroscience SE 33 participants Est. completion 2020-11 3 sites Stand-alone
    Other conditions: Primary Progressive Nonfluent Aphasia
    View official trial listing →
  • Enrolling by invitation NCT NCT07167966

    Alzheimer's Tau Platform: Regimen A - AADvac1

    Not yet reported Paul S. Aisen 450 participants Est. completion 2028-08-31 7 sites Stand-alone
    Other conditions: Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
    View official trial listing →
  • Enrolling by invitation NCT NCT07217665

    The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1

    Not yet reported Adam Boxer 146 participants Est. completion 2030-09-28 1 site Stand-alone
    Other conditions: PSP - Progressive Supranuclear Palsy
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.